Changes to the rare disease test directory are expected in April. Key changes include developmental disorders, chromosomal analysis, inherited cancer and neurological conditions.
Changes to the cancer test directory are expected in April. This includes the first moves towards a digital test directory and additional DPYD pharmacogenomic targets.